Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873174 | 0.87 | ITGB1 (0.48) | ITGB1ITGA4GAAALDH1A1 | |
| SCHEMBL2408947 | 0.87 | ITGB1 (0.48) | ITGB1ITGA4GAAALDH1A1 | |
| SCHEMBL2872923 | 0.87 | ITGB1 (0.48) | ITGB1ITGA4GAAALDH1A1 | |
| SCHEMBL20830618 | 0.83 | TSHR (0.38) | ITGB1ITGA4TSHRHDAC2ALDH1A1 | |
| SCHEMBL24378315 | 0.82 | ITGB1 (0.44) | ITGB1ITGA4GAAALDH1A1 | |
| SCHEMBL19869069 | 0.81 | CYP1A2 (0.49) | ITGB1ITGA4GAAALDH1A1 | |
| SCHEMBL11774610 | 0.80 | ITGB1 (0.57) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL11774604 | 0.80 | ITGB1 (0.57) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL24359843 | 0.80 | ITGB1 (0.57) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL22764801 | 0.79 | ITGB1 (0.43) | ITGB1ITGA4TLR2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590073-B2 | Method for preparation of N-acetyl cysteine amide and derivatives thereof | NACUITY PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019060623-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF | NACUITY PHARMACEUTICALS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| US-20190084926-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | NACUITY PHARMACEUTICALS, INC. | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590073-B2 | Method for preparation of N-acetyl cysteine amide and derivatives thereof | CTH, AHCY, AADAT | ITGB1 4539/4885ITGA4 3215/4885TSHR 2251/4885 |
| US-20190084926-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | CTH, AHCY, AADAT | ITGB1 4539/4885ITGA4 3215/4885TSHR 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.